Țară: Canada
Limbă: engleză
Sursă: Health Canada
CITALOPRAM (CITALOPRAM HYDROBROMIDE)
ANGITA PHARMA INC.
N06AB04
CITALOPRAM
30MG
TABLET
CITALOPRAM (CITALOPRAM HYDROBROMIDE) 30MG
ORAL
15G/50G
Prescription
Active ingredient group (AIG) number: 0136243004; AHFS:
APPROVED
2023-11-15
_AG-Citalopram Tablets (Citalopram Tablets BP) Product Monograph _ _Page 1 of 55 _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr AG-Citalopram Tablets Citalopram Tablets BP Tablet 30 mg Citalopram as Citalopram Hydrobromide, Oral BP Antidepressant Submission Control Number: 280131 Angita Pharma Inc. 1310 rue Nobel Boucherville, Quebec J4B 5H3, Canada Date of Initial Authorization: NOV 15, 2023 _AG-Citalopram Tablets (Citalopram Tablets BP) Product Monograph _ _Page 2 of 55 _ RECENT MAJOR LABEL CHANGES None at time of authorization. TABLE OF CONTENTS RECENT MAJOR LABEL CHANGES ............................................................................................. 2 TABLE OF CONTENTS ............................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION ....................................................................... 4 1 INDICATIONS .............................................................................................................. 4 1.1 Pediatrics .................................................................................................................. 4 1.2 Geriatrics .................................................................................................................. 4 2 CONTRAINDICATIONS ................................................................................................. 4 3 SERIOUS WARNINGS AND PRECAUTIONS .................................................................... 5 4 DOSAGE AND ADMINISTRATION ................................................................................. 5 4.1 Dosing Considerations .............................................................................................. 5 4.2 Recommended Dose and Dosage Adjustment ........................................................ 6 4.4 Administration .......................................................................................................... 8 4.5 Missed Dose ......... Citiți documentul complet